Pharmaceuticals News and Research

RSS

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.

9 Dec 2011

Sebelius overrules FDA on 'morning after' pill's OTC availability

The decision to keep the contraceptive pill "Plan B" behind the counter could shield the Obama administration from a bruising battle with conservatives but comes at the expense of liberal groups who are "shocked" at the decision.

9 Dec 2011

Paper calls for strong steps to control global crisis of antibiotic-resistant infections

Shahriar Mobashery, a University of Notre Dame researcher, is one of the coauthors of a new paper by a group of the world's leading scientists in academia and industry that calls for strong steps to be taken to control the global crisis of antibiotic resistance in bacteria. The group issued a priority list of steps that need to be taken on a global scale to resolve the crisis.

9 Dec 2011

Menarini, Moberg Derma partner to distribute Emtrix in Italy

Moberg Derma AB has entered into a distribution agreement with Menarini Group for Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

9 Dec 2011

Pharmaceutical spam leads patients to seek out online information about prescription drugs

Spam advertising of pharmaceutical products is leading patients to seek out information about prescription drugs online, according to a report to be published in the International Journal Business and Systems Research. If those drugs are not available to the internet user through their physician there is a risk that they may obtain such products via illicit means.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

USPTO issues Diabetes Patent to Omni Bio

Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011. The Diabetes Patent expires in May 2022.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Toxins in Danish mushroom are effective against cancer cells

Researchers at the University of Copenhagen have explored the active principles of a Danish mushroom and found that some of the substances it contains are particularly toxic towards cancer cells. The goal is to synthesise and refine substances in the mushroom that may be useful in future drug development.

9 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Global health R&D funding from wealthy nations fell 6% in 2010, annual G-FINDER report finds

"A group that tracks funding for neglected diseases released its fourth annual report Wednesday, showing for the first time since 2007 a decrease in government and public spending in global health research and development," the Center for Global Health Policy's "Science Speaks" blog reports.

8 Dec 2011

FDA advisory panel OKs anemia drug peginesatide

Once approved by the FDA, the once-monthly injection could capture a share of the $3 billion U.S. market for anemia drugs used for kidney dialysis patients, currently dominated by Amgen Inc's blockbuster Epogen. Affymax, which developed the drug with partner Takeda Pharmaceutical Co Ltd, is also expected to price its product below Epogen.

8 Dec 2011

Sebelius overturns FDA on morning after pill access

The Health and Human Services Secretary Kathleen Sebelius this Wednesday has overturned the Food and Drug Administration's plan to remove the age limit on who can buy Teva Pharmaceutical Industries Ltd's Plan B One-Step pill – commonly known as the “morning after pill” without a prescription.

8 Dec 2011

Cubist, Adolor announce results of initial tender offer

Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.

8 Dec 2011

Heart patients may experience fewer traumas with new invention

Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.

8 Dec 2011

NIH, EPA and FDA collaborate to move science forward

A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, begins today to test 10,000 compounds for potential toxicity. The compounds cover a wide variety of classifications, and include consumer products, food additives, chemicals found in industrial processes, and human and veterinary drugs.

8 Dec 2011

HHS: Plan B access will stay limited

The Department of Health and Human Services announced today that the morning-after pill, known as Plan B, will continue to be kept behind the pharmacy counter and girls younger than 17 will continue to need a prescription to obtain it.

8 Dec 2011

State roundup: Aetna suing over Mich. BCBS hospital deals; ACLU threatens Ohio abortion suit

The latest challenge was a lawsuit filed Tuesday in Detroit's federal court by insurance giant Aetna, one of the nation's largest health plans, with 35 million members. The suit alleges a violation of federal antitrust laws, claiming the Blues raised rates for Michigan consumers over the last four years and used the money to reward hospitals with higher payments if they charged Blues' competitors the same or higher rates.

8 Dec 2011

Janssen Biotech, Molecular Partners collaborate to develop DARPins for immunological diseases

Molecular Partners AG today announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin products for the treatment of immunological diseases.

8 Dec 2011

Pharmaceuticals News and Research

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Sebelius overrules FDA on 'morning after' pill's OTC availability

Paper calls for strong steps to control global crisis of antibiotic-resistant infections

Menarini, Moberg Derma partner to distribute Emtrix in Italy

Pharmaceutical spam leads patients to seek out online information about prescription drugs

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

USPTO issues Diabetes Patent to Omni Bio

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Toxins in Danish mushroom are effective against cancer cells

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

Global health R&D funding from wealthy nations fell 6% in 2010, annual G-FINDER report finds

FDA advisory panel OKs anemia drug peginesatide

Sebelius overturns FDA on morning after pill access

Cubist, Adolor announce results of initial tender offer

Heart patients may experience fewer traumas with new invention

NIH, EPA and FDA collaborate to move science forward

HHS: Plan B access will stay limited

State roundup: Aetna suing over Mich. BCBS hospital deals; ACLU threatens Ohio abortion suit

Janssen Biotech, Molecular Partners collaborate to develop DARPins for immunological diseases

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence